BioTech Medics, Inc., Enters LOI With Nutriceutical Co. Harwood Enterprises, LP
07 2월 2006 - 11:00PM
PR Newswire (US)
DALLAS, Feb. 7 /PRNewswire-FirstCall/ -- BioTech Medics, Inc. (OTC
Pink Sheets: BTMD) has entered into a Letter of Intent to acquire
specified BioBody Product formula, trademarks and copyrights of
Harwood Enterprises Worldwide, LP. Keith Houser, CEO, stated, "As a
part of our pledge to increase the value of BTMD, BioTech Medics
Wellness program, we want to offer some of the best nutriceutical
health products available to our clientele. Harwood has over a half
dozen proven products which complement our goals and objectives of
wellness. Harwood also brings the expertise and knowledge to help
BTMD to finish developing our exclusive and patented SHBAN
products." Harwood is an eight-year-old Texas company that offers
proprietary ingredient patented products which help the body to
function at its best. The main line product is BioBody Balance(TM).
The line of Harwood Products are featured on the web at
http://www.uniqueformulas.com/ . Harwood has had Gross Revenues of
$1.5 million annually for the past 3 years aggregating Combined
Gross Revenues of $4.5 million. The stock acquisition is estimated
to be valued at $5 million. Closing is to take place on or before
March 3, 2006. BioTech Medics is a distributor of the NeuroLase
Therapeutic Medical Laser. The NeuroLase provides relief from
muscular, skeletal and arthritic pain. BTMD operates a Pain
Management & Wellness Center in Dallas with Charles R. Crane,
MD. BTMD plans on closing on more new Pain Management &
Wellness Centers in 2006, as well as acquiring a permanent office
building in Dallas, Texas. BioTech pledges to strive to add more
assets and increased revenue for the company to bring more value to
the stock and its more than 5,800 shareholders in 22 countries.
Contact: BioTech Medics, Inc., at 972-274-5533 Check BTMD Out On
the Web at http://www.biotechmedics.com/ Safe Harbor for
Forward-Looking Statements This press contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995 (the "Act"). In Particular, when used in the
preceding discussion, the words "plan," "confident that,"
"believe," "scheduled," "expect," or "intend to," and similar
conditional expressions are intended to identify forward-looking
statements within the meaning of the Act and are subject to the
safe harbor created by the Act. Such statements are subject to
certain risks and uncertainties and actual results could differ
materially from those expressed in any of the forward-looking
statements. DATASOURCE: BioTech Medics, Inc. CONTACT: BioTech
Medics, Inc., +1-972-274-5533 Web site:
http://www.biotechmedics.com/ http://www.uniqueformulas.com/
Copyright